CN101939303B - 波生坦的晶型 - Google Patents

波生坦的晶型 Download PDF

Info

Publication number
CN101939303B
CN101939303B CN200880122464.2A CN200880122464A CN101939303B CN 101939303 B CN101939303 B CN 101939303B CN 200880122464 A CN200880122464 A CN 200880122464A CN 101939303 B CN101939303 B CN 101939303B
Authority
CN
China
Prior art keywords
bosentan
crystalline form
crystalline
solid
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880122464.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN101939303A (zh
Inventor
阿沛·盖顿德
宾杜·马诺杰库马
桑迪普·梅克德
普拉卡什·班索德
达塔特拉亚·希恩德
苏纳达·菲德塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CN101939303A publication Critical patent/CN101939303A/zh
Application granted granted Critical
Publication of CN101939303B publication Critical patent/CN101939303B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880122464.2A 2007-10-24 2008-10-24 波生坦的晶型 Expired - Fee Related CN101939303B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2108/MUM/2007 2007-10-24
IN2108MU2007 2007-10-24
PCT/GB2008/050986 WO2009053748A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Publications (2)

Publication Number Publication Date
CN101939303A CN101939303A (zh) 2011-01-05
CN101939303B true CN101939303B (zh) 2014-06-11

Family

ID=40262729

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880122464.2A Expired - Fee Related CN101939303B (zh) 2007-10-24 2008-10-24 波生坦的晶型

Country Status (8)

Country Link
US (1) US8530488B2 (https=)
EP (1) EP2222649A2 (https=)
JP (1) JP2011500780A (https=)
CN (1) CN101939303B (https=)
AU (1) AU2008315757A1 (https=)
CA (1) CA2703230A1 (https=)
NZ (2) NZ585438A (https=)
WO (1) WO2009053748A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008247169B2 (en) * 2007-05-08 2013-09-12 Generics [Uk] Limited Polymorphic forms of bosentan
US8664390B2 (en) * 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
JP2011500780A (ja) * 2007-10-24 2011-01-06 ジェネリクス・（ユーケー）・リミテッド 新規結晶形
JP5535082B2 (ja) * 2008-01-01 2014-07-02 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
WO2010032261A1 (en) 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526708A1 (de) * 1991-06-13 1993-02-10 F. Hoffmann-La Roche Ag Sulfonamide, ihre Herstellung und Verwendung als Heilmittel und Zwischenprodukte
CN1425007A (zh) * 2000-01-25 2003-06-18 弗·哈夫曼-拉罗切有限公司 磺酰胺的制备

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
EP2206497A1 (en) 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1411373A (zh) 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
AU2003230195A1 (en) 2003-04-02 2004-10-25 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
AU2008247169B2 (en) 2007-05-08 2013-09-12 Generics [Uk] Limited Polymorphic forms of bosentan
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) * 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
JP2011500780A (ja) * 2007-10-24 2011-01-06 ジェネリクス・（ユーケー）・リミテッド 新規結晶形
ES2376375T3 (es) 2007-12-18 2012-03-13 Dipharma Francis S.R.L. Procedimiento para la preparación de bosent�?n.
EP2240470A4 (en) 2008-01-10 2012-05-23 Msn Lab Ltd IMPROVED AND NEW PROCESS FOR THE PRODUCTION OF BOSENTANE
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
EP2268634A2 (en) 2008-03-13 2011-01-05 Actavis Group PTC EHF Processes for the preparation of bosentan and related compounds using novel intermediates
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526708A1 (de) * 1991-06-13 1993-02-10 F. Hoffmann-La Roche Ag Sulfonamide, ihre Herstellung und Verwendung als Heilmittel und Zwischenprodukte
CN1425007A (zh) * 2000-01-25 2003-06-18 弗·哈夫曼-拉罗切有限公司 磺酰胺的制备

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Research and Development of a Second-Generation Process for Bosentan,an Endothelin Receptor Antagonist;Harrington P. J. et al;《Organic Process Research & Development》;20020205;第6卷;120-124 *
内皮素受体阻断剂波生坦的合成;杨宁等;《中国药物化学杂志》;20050831;第15卷(第4期);230-234 *

Also Published As

Publication number Publication date
AU2008315757A1 (en) 2009-04-30
EP2222649A2 (en) 2010-09-01
JP2011500780A (ja) 2011-01-06
CN101939303A (zh) 2011-01-05
US8530488B2 (en) 2013-09-10
NZ600010A (en) 2013-11-29
WO2009053748A2 (en) 2009-04-30
NZ585438A (en) 2012-09-28
US20100331352A1 (en) 2010-12-30
CA2703230A1 (en) 2009-04-30
WO2009053748A3 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
CN101939303B (zh) 波生坦的晶型
JP4559431B2 (ja) 固体及び結晶イバンドロネートナトリウム及びその調製方法
AU2008247169B2 (en) Polymorphic forms of bosentan
CN102272118A (zh) 来那度胺的晶型及其制备方法
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
JP2007526251A (ja) エゼチミベ多形体
KR20080060284A (ko) 결정질 로수바스타틴 칼슘
KR20080055990A (ko) 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
JP2013528206A (ja) 結晶形態のサリドマイド及びその調製方法
WO2017109772A1 (en) Amorphous form of selexipag
JP2005534633A (ja) ガチフロキサシンの新規結晶形
US20090018182A1 (en) Crystalline forms of atorvastatin
KR20070072588A (ko) 텔미사르탄 나트륨의 비정질형 및 다형
WO2014016842A1 (en) Amorphous coprecipitates of rivaroxaban
JP2006508909A (ja) ガチフロキサシンの新規な結晶形
WO2013166966A1 (zh) 含氟的氘代ω-二苯基脲或其盐的多晶型物
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법
WO2025141465A1 (en) Solid state forms of zipalertinib hydrochloride and process for preparation thereof
JP2008504369A (ja) １，２４（ｓ）−ジヒドロキシビタミンｄ２の結晶形態
AU2013200937A1 (en) Polymorphic forms of bosentan

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140611

Termination date: 20141024

EXPY Termination of patent right or utility model